Document:

EX-10.2

 Exhibit 10.2 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on this 22nd day of May, 2015 by and between Corindus Vascular
Robotics, Inc., a Nevada corporation with its principal office in Waltham, Massachusetts (the “Company”), and David W. Long (“Executive”) and is effective as of the closing date of the first public offering of the Company’s
common stock after the date hereof (the “Effective Date”). Any reference herein to “Corindus” shall mean Corindus, Inc., a wholly-owned subsidiary of the Company. 

WHEREAS, the Executive is currently employed as Senior Vice President and Chief Financial Officer of the Company and Corindus subject to an
offer letter with Corindus dated August 4, 2011, an “Acknowledgment – Conditions of Employment” between Corindus and Executive dated August 4, 2011, a termination agreement with HealthCor Partners dated June 4, 2014 and
a memorandum from Corindus regarding employment terms dated June 4, 2014 (collectively, the “Prior Agreements”); 
 WHEREAS,
the Company and Corindus desire to replace the Prior Agreements with the Executive so that the Company and Corindus are assured of the continued availability of the Executive’s services as provided in this Agreement; 

WHEREAS, the Executive is willing to serve the Company and its subsidiaries, including Corindus, on the terms and conditions hereinafter set
forth; and 
 WHEREAS, the parties hereto desire to set forth the terms of an employment agreement and the continuing employment
relationship with the Executive. 
 NOW, THEREFORE, in consideration of the mutual covenants herein contained, and upon the other terms and
conditions hereinafter provided, the parties hereby agree as follows: 
 1. Period of Employment. The Company hereby agrees to employ
the Executive, and the Executive hereby accepts employment with the Company upon the terms set forth in this Agreement, on an at will basis for the period commencing on the Effective Date and ending on the date the Executive’s employment is
terminated pursuant to the terms of this Agreement (with such period being referred to herein as the “Employment Period”). The Executive’s employment with the Company is voluntary and he is free to resign at any time, subject to the
provisions of this Agreement. Further, the Company will be free to terminate the Executive’s employment at any time, with or without cause and without further obligation or liability, subject to the provisions of this Agreement. 

2. Title; Capacity. The Executive shall serve as Senior Vice President and Chief Financial Officer of the Company or in such other
position as the Board may determine from time to time, including but not limited to as an officer and director of any subsidiary or affiliate of the Company, including Corindus. The Executive shall be based at the Company’s headquarters in
Waltham, Massachusetts, or such place or places in the Greater Boston area as the Board shall determine. The Executive shall be subject to the supervision of, and shall have such authority as is delegated to the Executive by the Chief Executive
Officer. 

 The Executive hereby accepts such employment and agrees to undertake the duties and
responsibilities inherent in such position (including but not limited to those set forth in the charter or bylaws of the Company) and such other duties and responsibilities as the Board or the Chief Executive Officer shall from time to time
reasonably assign to the Executive. Except for periods of absence occasioned by illness, reasonable vacation periods, and reasonable leaves of absence approved by the Board, the Executive agrees to devote his entire business time, attention and
energies to the business and interests of the Company during the Employment Period. The Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein which may be adopted
from time to time by the Company. 
 The compensation and benefits specified under this Agreement shall constitute the sole remuneration for
the duties and responsibilities described in this Section 2. 
 3. Compensation and Benefits. 

3.1 Base Salary. The Company or Corindus shall pay the Executive, in periodic installments in accordance with the Company’s
customary payroll practices, an annual base salary of $275,000 subject to annual review for adjustment as determined by the Board, it being understand that such review may be conducted by the compensation committee designated by the Board (the
“Committee”). Any increase in base salary in effect from time to time shall become the base salary for purposes of this Agreement. 

3.2 Annual Bonus. The Executive will be eligible for a bonus payment of up to 50% (or such higher percentage set by the Board) of his
annual salary for the year immediately preceding payment of such bonus based on achievement of performance objectives (as reasonably determined by the Board) contained in an annual plan approved by the Board. Any action under this Section 3.2
may be taken by the Committee as deemed to be appropriate by the Board. Any bonus award will be paid on or before March 15 of the fiscal year following the fiscal year in which the bonus was earned, and conditioned upon the Executive’s
employment with the Company at the end of the immediately preceding fiscal year. The annual bonus for the Company’s 2015 fiscal year shall be paid on the terms and conditions determined previously by the Board. 

3.3 Fringe Benefits; Vacation. The Executive shall be entitled to participate in all fringe benefit programs that the Company
establishes and makes available to its employees, if any, to the extent that Executive’s position, tenure, salary, age, health and other qualifications make him eligible to participate. The Executive shall be entitled to four (4) weeks
paid vacation per year, to be taken at such times as may be approved by the Board or its designee. Vacation days must be taken during the calendar year with no carryover of vacation days to the following 12-month period. Nothing contained herein
shall be construed to limit the Company’s ability to amend, suspend, or terminate any fringe benefit program at any time without providing the Executive notice, and the right to do so is expressly reserved. 

3.4 Reimbursement of Expenses. The Company shall reimburse the Executive for all reasonable travel, entertainment and other expenses
incurred or paid by the Executive in connection with, or related to, the performance of his duties, responsibilities or services under this Agreement, in accordance with policies and procedures, and subject to limitations, adopted by the Company
from time to time. 
 3.5 Withholding; Section 409A. All salary, bonus and other compensation payable to the Executive shall be
subject to applicable withholding taxes. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code and the guidance issued
thereunder (“Section 409A”) to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement be for expenses incurred during
Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other
calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or
liquidation or exchange for any other benefit. 

  
 2 

 4. Termination of Employment Period. The employment of the Executive by the Company
pursuant to this Agreement shall terminate upon the occurrence of any of the following: 
 4.1 At the election of the Company, for Cause (as
defined below), immediately upon written notice by the Company to the Executive, which notice shall identify the Cause upon which the termination is based. For the purposes of this Section 4.2, “Cause” shall mean (a) a good faith
finding by the Board that (i) the Executive has intentionally failed to perform his assigned duties for the Company, or (ii) the Executive has engaged in dishonesty, breach of fiduciary duty involving personal profit, gross negligence,
misconduct, material breach of the Company’s Code of Ethics, or a material violation of the Sarbanes-Oxley requirements for officers of public companies, (b) the conviction of the Executive of, or the entry of a pleading of guilty or nolo
contendere by the Executive to, any crime involving moral turpitude or any felony, or (c) a material breach by the Executive of this Agreement. 

4.2 Upon the death or disability of the Executive. As used in this Agreement, the term “disability” shall mean the inability of the
Executive, due to a physical or mental disability, for a period of ninety (90) days, whether or not consecutive, during any 360-day period to perform the services contemplated under this Agreement, with or without reasonable accommodation as
that term is defined under state or federal law. A determination of disability shall be made by a physician satisfactory to both the Executive and the Company, provided that if the Executive and the Company do not agree on a physician, the Executive
and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding on all parties. 

4.3 At the election of the Executive for Good Reason. For purposes of this Section 4.3, “Good Reason” shall mean any of the
following: (i) a material negative change in the Executive’s function, duties, or responsibilities, (ii) a reduction to base salary (except for any reduction that is part of an employee-wide reduction in pay), (iii) a requirement
to relocate outside the Greater Boston area; or (iv) a material breach of this Agreement by the Company. Upon the occurrence of any event described above, the Executive shall have the right to elect to

  
 3 

 
terminate his employment under this Agreement by resignation upon not less than thirty (30) days prior written notice given within a reasonable period of time (not to exceed, except in case
of a continuing breach, ninety (90) days) after the event giving rise to said right to elect a Good Reason termination. The Company, Corindus or both shall have at least thirty (30) days to remedy any condition resulting in Good Reason.

 4.4 At the election of either party, upon not less than thirty (30) days’ prior written notice of termination. 

5. Effect of Termination. 

5.1 Payments Benefits upon Termination of Employment without Cause or Executive Termination for Good Reason. In the event that the
Executive’s employment is terminated by the Company without Cause or the Executive resigns for Good Reason, whether before or after a Change in Control (as defined in Section 5.2 below), the Company shall provide the Executive with the
following payments and benefits: 
 (a) continued payment of his base salary for twelve months, 

(b) payment of the monthly amount then being charged by the Company or Corindus for COBRA coverage with respect to the Executive and his
dependents for twelve months, 
 (c) payment of one-twelfth of amount of annual bonus accrued on the Company’s books and records as of
the end of the immediately preceding calendar quarter for twelve months, and 
 (d) release from any restrictions in a lock-up agreement
with respect to stock that may be acquired by exercising any then outstanding and vested stock option granted by the Company or Corindus; 
 provided,
however, that the payments described in paragraphs (a) and (b) above shall cease upon violation of any covenant under Section 6 of this Agreement or as provided under the mitigation provisions in Section 8 below. Receipt of the
foregoing payments benefits shall be conditioned on the Executive executing and not revoking a standard form of release of the Company and associated persons from any claims against them within 30 days of the date of his employment termination. The
benefits and payments to be made hereunder (A) shall commence 30 days following the Executive’s termination of employment, provided that the release referenced in the prior sentence has been signed and not revoked as of such date,
(B) shall, if payable in cash, continue to be made in accordance with the Company’s regular payroll schedule practices and (C) shall be subject to the terms and conditions set forth in Exhibit A. 

5.2 Change in Control Protection. One hundred percent (100%) of the Executive’s outstanding unvested stock options will
automatically vest upon a Change in Control, provided that the Executive is then employed with the Company. Any other type of equity award that may be granted by the Company after the Effective Date will provide for 100% accelerated vesting in the
event of a Qualifying CIC Termination, in such form as the Board or Committee determines is appropriate. For purposes of this Agreement, (a) a “Change in 

  
 4 

 
Control” shall mean a “Change in Control” as defined under the Corindus Vascular Robotics, Inc. 2014 Stock Award Plan, as in effect on the Effective Date, and (b) a
“Qualifying CIC Termination” shall mean, on or within twelve months of a Change in Control, the Executive’s termination of employment with the Company for Good Reason or the Company’s termination of the Executive’s without
Cause. 
 5.3 Accrued Obligations. The Executive shall be entitled to payment of any outstanding Accrued Obligation as of the date of
employment termination for any reason without any requirement to sign a release. For purposes of this section 5.3, “Accrued Obligations” means (i) all accrued but unpaid base salary through the date of employment termination,
(ii) any unpaid or unreimbursed expenses incurred through the date of employment termination in accordance with Section 3.4 above, (iii) annual bonus, if any, earned during the prior calendar year under Section 3.2 above,
provided that the Executive was employed with the Company or Corindus at the end of such year, and (iv) any benefits provided under the Company’s fringe benefit programs upon a termination of employment, in accordance with the terms
contained therein. 
 5.4 Survival. The provisions of Sections 6 and 7 shall survive the termination of this Agreement. 

6. Non-Competition and Non-Solicitation. 

6.1 Restricted Activities. While the Executive is employed by the Company and for a period of eighteen (18) months after the
termination or cessation of such employment for any reason, the Executive will not directly or indirectly: 
 (a) Engage in any business or
enterprise (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that is competitive with the Company’s
Business, including but not limited to any business or enterprise that develops, manufactures, markets, licenses, sells or provides any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or
provided, or planned to be developed, manufactured, marketed, licensed, sold or provided, by the Company while the Executive was employed by the Company; or 

(b) Either alone or in association with others (i) solicit, or permit any organization directly or indirectly controlled by the
Executive to solicit, any employee of the Company to leave the employ of the Company, or (ii) solicit for employment, hire or engage as an independent contractor, or permit any organization directly or indirectly controlled by the Executive to
solicit for employment, hire or engage as an independent contractor, any person who was employed by the Company at any time during the term of the Executive’s employment with the Company. 

(c) For purposes of this Section 6.1, “Company’s Business” shall mean the development, manufacture, marketing, licensing
or sales of the products or services of the Company in the field of vascular robotics. 
 (d) For purposes of Section 6 and
Section 7, the term “Company” includes the Company’s subsidiaries, including Corindus. 

  
 5 

 6.2 Extension. If the Executive violates the provisions of Section 6.1, the Executive
shall continue to be bound by the restrictions set forth in Section 6.1 until a period of eighteen (18) months has expired without any violation of such provisions. 

6.3 Interpretation. If any restriction set forth in Section 6.1 is found by any court of competent jurisdiction to be
unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area
as to which it may be enforceable. 
 6.4 Equitable Remedies. The restrictions contained in this Section 6 are necessary for the
protection of the business and goodwill of the Company and are considered by the Executive to be reasonable for such purpose. The Executive agrees that any breach of this Section 6 is likely to cause the Company substantial and irrevocable
damage which is difficult to measure. Therefore, in the event of any such breach or threatened breach, the Executive agrees that the Company, in addition to such other remedies which may be available, shall have the right to apply for an injunction
from a court restraining such a breach or threatened breach and the right to specific performance of the provisions of this Section 6. 

7. Proprietary Information and Developments. 

7.1 Proprietary Information. 

(a) The Executive agrees that all information, whether or not in writing, of a private, secret or confidential nature concerning the
Company’s business, business relationships, technologies, products, product development and marketing strategics or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. By
way of illustration, but not limitation, Proprietary Information may include inventions, products, processes, methods, trade secrets, formulas, compositions, compounds, projects, developments, plans, research data, clinical data, financial data,
personnel data, computer programs, customer and supplier lists, and knowledge of customers or prospective customers of the Company. The Executive will not disclose any Proprietary Information to any person or entity other than employees of the
Company or use the same for any purposes (other than in the performance of his duties as an employee of the Company) without written approval by an officer of the Company, either during or after his employment with the Company, unless and until such
Proprietary Information has become public knowledge without fault by the Executive. 
 (b) The Executive agrees that all files, letters,
memoranda, reports, records, data, sketches, drawings, laboratory notebooks, program listings, or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Executive or others, which shall
come into his custody or possession, shall be and are the exclusive property of the Company to be used by the Executive only in the performance of his duties for the Company. All such materials or copies thereof and all tangible property of the

  
 6 

 
Company in the custody or possession of the Executive shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) termination of his employment. After
such delivery, the Executive shall not retain any such materials or copies thereof or any such tangible property. 
 (c) The Executive
agrees that his obligation not to disclose or to use information and materials of the types set forth in paragraphs (a) and (b) above, and his obligation to return materials and tangible. property, set forth in paragraph (b) above,
also extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Executive. 

7.2 Developments. 
 (a)
The Executive will make full and prompt disclosure to the Company of all inventions, improvements, discoveries, methods, developments, software, and works of authorship, whether patentable or not, which are created, made, conceived or reduced to
practice by him or under his direction or jointly with others during his employment by the Company, whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this Agreement as
“Developments”). 
 (b) The Executive agrees to assign and does hereby assign to the Company (or any person or entity designated
by the Company) all his right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications. However, this paragraph (b) shall not apply to Developments which do not relate to
the business or research and development conducted or planned to be conducted by the Company at the time such Development is created, made, conceived or reduced to practice and which are made and conceived by the Executive not during normal working
hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Proprietary Information. The Executive understands that, to the extent this Agreement shall be construed in accordance with the laws of any state
which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph (b) shall be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within
such classes. The Executive also hereby waives all claims to moral rights in any Developments. 
 (c) The Executive agrees to cooperate
fully with the Company, both during and after his employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign
countries) relating to Developments; provided that, after his employment with the Company, such cooperation shall be conditioned upon reimbursement by the Company of the Executive’s reasonable costs and expenses incurred in connection
therewith. The Executive shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem
necessary or desirable in order to protect its rights and interests in any Development. The Executive further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Executive on any such papers, any executive
officer of the Company shall be entitled to execute any such papers as the agent and 

  
 7 

 
the attorney-in-fact of the Executive, and the Executive hereby irrevocably designates and appoints each executive officer of the Company as his agent and attorney-in-fact to execute any such
papers on his behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence, 

7.3 United States Government Obligations. The Executive acknowledges that the Company from time to time may have agreements with other
parties or with the United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work.
The Executive agrees to be bound by all such obligations and restrictions which are made known to the Executive and to take all appropriate action necessary to discharge the obligations of the Company under such agreements. 

7.4 Equitable Remedies. The restrictions contained in this Section 7 are necessary for the protection of the business and goodwill
of the Company and are considered by the Executive to be reasonable for such purpose. The Executive agrees that any breach of this Section 7 may cause the Company substantial and irrevocable damage which is difficult to measure. Therefore, in
the event of any such breach or threatened breach, the Executive agrees that the Company, in addition to such other remedies which may be available, shall have the right to apply for an injunction from a court restraining such a breach or threatened
breach and the right to specific performance of the provisions of this Section 7. 
 8. Mitigation. Subject to the
non-competition provisions in Section 6 above, the Executive shall be required to mitigate the amount of any payment provided for under Section 5.1(a) and Section 5.1(b) by seeking other employment or remunerative activity reasonably
comparable to his duties under this Agreement. Upon the Executive’s obtaining such other employment or remunerative activity, any future payments under Sections 5.1(a) and 5.1(b) shall be discontinued. Notwithstanding the foregoing, the
Executive shall not be required to mitigate, and there shall be no forfeiture of future payments under Sections 5.1(a) and 5.1(b), in the event that on or after a Change in Control (as defined in Section 5.2 above) either the Executive
terminates his employment hereunder for Good Reason or the Company terminates the Executive’s employment without Cause. 
 9.
Clawback; Recovery. All payments and severance benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company adopts pursuant to the listing standards of any national securities exchange
or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. For avoidance of doubt, no recovery of compensation under such a
clawback policy will be an event giving rise to Good Reason for employment termination by the Executive, constructive termination, or any similar term under any plan of or agreement with the Company, Corindus or its subsidiaries. 

10. Miscellaneous. 
 10.1
Notices. Any notices delivered under this Agreement shall be deemed duly delivered four (4) business days after it is sent by registered or certified mail, return receipt 

  
 8 

 
requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, in each case to the address of the recipient
set forth in the introductory paragraph hereto. Either party may change the address to which notices are to be delivered by giving notice of such change to the other party in the manner set forth in this Section 10.1. 

10.2 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 10.3 Entire
Agreement. This Agreement contains the entire understanding between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement, including but not limited to the
Prior Agreements; provided, however, that the provisions of the Key Employee Nondisclosure, Confidentiality, Assignment and Non-Competition Agreement shall continue to apply in addition to this Agreement. No provision of this Agreement shall be
interpreted to mean that Executive is subject to receiving fewer benefits than those available to him without reference to this Agreement. 

10.4 Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.

 10.5 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of The Commonwealth of
Massachusetts (without reference to the conflicts of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court of The Commonwealth of
Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Executive each consents to the jurisdiction of such a court. 

10.6 Successors and Assigns; Third Party Beneficiaries. This Agreement shall be binding upon and inure to the benefit of both the
Company and its successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business; provided, however, that the obligations of the Executive are
personal and shall not be assigned by him. Corindus and each of the Company’s other direct and indirect subsidiaries are designated as a third party beneficiary of this Agreement and shall be entitled to enforce the terms hereof as if it were a
party hereto. In addition, HealthCor shall be a third party beneficiary with respect to the provisions of Section 10.3 above with respect to Prior Agreements. 

10.7 Section 409A. The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A,
and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. Notwithstanding the immediately preceding sentence, in no event shall the Company, Corindus
or any of their respective subsidiaries be liable for any additional tax, interest, or penalties that may be imposed on Executive as a result of Section 409A or any damages for failing to comply with Section 409A (other than for
withholding obligations or other obligations applicable to employers under the Code). 

  
 9 

 10.8 Source of Payments. Notwithstanding any provision in this Agreement to the contrary,
there will be no duplication of benefits between this Agreement and the Prior Agreements and any other agreement to which the Executive may be subject with Corindus. To the extent payments and benefits, as provided for under this Agreement, are paid
or received by Executive under one or more of the Prior Agreements, the payments and benefits paid by Corindus will be subtracted from any amount or benefit due simultaneously to Executive under similar provisions of this Agreement. 

10.9 Waivers. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any
other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

10.10 Captions. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or
affect the scope or substance of any section of this Agreement. 
 10.11 Severability. In case any provision of this Agreement shall
be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby, 

THE EXECUTIVE ACKNOWLEDGES THAT HE HAS READ THIS AGREEMENT CAREFULLY AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above. 

 

			
	CORINDUS VASCULAR ROBOTICS, INC.
		
	By:		 /s/ David M. Handler

		
	Title:		 Chief Executive Officer

	
	EXECUTIVE
	
	 /s/ David W. Long

	David W. Long

  
 10 

 Exhibit A: Payments subject to Section 409A 

Subject to the provisions in this Exhibit A, any severance payments or benefits under this Agreement shall begin only upon the date of the
Executive’s “separation from service” (determined as set forth below) which occurs on or after date of the termination of his employment. The following rules shall apply with respect to distribution of the payments and benefits, if
any, to be provided to the Executive under this Agreement: 
 1. It is intended that each installment of severance payments and benefits
provided under this Agreement shall be treated as a separate “payment” for purposes of Section 409A. Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits
except to the extent specifically permitted or required by Section 409A. 
 2. Each installment of the severance payments and benefits
due under this Agreement that, in accordance with the dates and terms set forth herein, is payable within the Short-Term Deferral Period (as hereinafter defined) shall be treated as a short-term deferral within the meaning of Treasury Regulation
Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A. For purposes of this Agreement, the “Short-Term Deferral Period” means the period ending on the later of the 15th day of the third month following the
end of the Executive’s tax year in which the separation from service occurs and the 15th day of the third month following the end of the Company’s tax year in which the separation from service occurs. 

3. Each installment of the severance payments and benefits due under this Agreement that is not described in either paragraph 2 above and that
would, absent this subsection, be paid within the six-month period following the Executive’s “separation from service” from the Company shall not be paid until the date that is six months and one day after such separation from service
(or, if earlier, the Executive’s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive’s
separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance
payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of the
Executive’s second taxable year following the taxable year in which the separation from service occurs. 
 4. The determination of
whether and when the Executive’s separation from service from the Company has occurred shall be made and in a manner consistent with and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes
of this paragraph 4, “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(e) of the Code.EX-10.16

 Exhibit 10.16 

CORINDUS VASCULAR ROBOTICS, INC. 

2014 STOCK AWARD PLAN 

STOCK OPTION GRANT NOTICE 

Corindus Vascular Robotics, Inc., a Nevada corporation, (the “Company”), pursuant to the Corindus Vascular Robotics,
Inc. 2014 Stock Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Common
Stock (the “Shares”) set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein and in the Stock Option Agreement, attached hereto (the “Stock
Option Agreement”), and the Plan (a copy of which has been provided to Participant), both of which are incorporated herein in their entirety. Any capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in
the Plan or the Grant Notice. 
  

			
	Participant:		[                                      
  ]
		
	Date of Grant:		[                                      
  ]
		
	Exercise Price per Share:		$[            ]
		
	Total Exercise Price:		$[                    ]
		
	Total Number of Shares Subject to the Option:		[                    ] Shares
		
	Expiration Date:		10 Years after the Date of Grant
		
	Vesting Schedule:		 50% on the 1st anniversary of the Date of Grant and 100% on the 2nd anniversary of the
Date of Grant, provided the Participant is then providing services to the Company and its Affiliates.
  

100% vesting upon a Change in Control (as defined under the Plan), provided the Participant is then providing services to the Company and its
Affiliates.

		
	Type of Option:		Nonqualified Stock Option

 Additional Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Grant
Notice, the Stock Option Agreement, and the Plan. Participant further acknowledges that as of the Date of Grant, this Grant Notice, the Stock Option Agreement, including Exhibit A — Form of Lock-up Agreement, and the Plan set forth the
entire understanding between Participant and the Company regarding the acquisition of Shares and supersede all prior oral and written agreements on that subject with the exception of any stock options previously granted and delivered to Participant
under the Plan. Participant further acknowledges receipt of the Company’s prospectus covering the Shares issuable upon exercise of the Option and that he or she has read and understands such prospectus. 

 

									
	CORINDUS VASCULAR ROBOTICS, INC.				PARTICIPANT
					
	By:		  
				By:		  

	Print Name:		  
				Print Name:		  

	Title:		  
						

 CORINDUS VASCULAR ROBOTICS, INC. 

2014 STOCK AWARD PLAN 

STOCK OPTION AGREEMENT 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement (this
“Agreement”) Corindus Vascular Robotics, Inc. (the “Company”) has granted you a stock option under the Corindus Vascular Robotics, Inc. 2014 Stock Award Plan, as amended from time to time (the
“Plan”), to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the Exercise Price indicated in your Grant Notice. Capitalized terms not defined in this Agreement but defined in
the Plan shall have the same definitions as in the Plan. For the avoidance of doubt, the terms and conditions of the Grant Notice are a part of this Agreement, unless otherwise specified. 

The details and terms and conditions of this Agreement shall govern your Option: 

1. VESTING. 

(a) Subject to the limitations contained herein and Section 1(b) below, the Option will vest as set forth in your Grant Notice,
provided, that vesting will cease upon the termination of your services as an Eligible Person (as defined in the Plan). For purposes of this Agreement, in the event of an involuntary termination of your service with the Company and its
Affiliates, the termination shall be effective, and vesting shall cease, as of the date stated in the relevant notice of termination and, unless otherwise required by law, will not be extended by any notice period or other period of leave. Subject
to applicable law, the Company shall determine the date of termination in its sole discretion. 
 (b) Notwithstanding any other
provision of this Agreement to the contrary, your rights to vest under this Agreement will be subject at all times to your compliance with Section 15 below. 

2. NUMBER OF SHARES AND EXERCISE
PRICE. The number of Shares subject to the Option and the Exercise Price per Share referenced in your Grant Notice may be adjusted from time to time for various adjustments in the Company’s equity capital
structure, as provided in Section 12 of the Plan. 
 3. METHOD OF
PAYMENT. Payment of the aggregate Exercise Price for the Shares for which the Option is being exercised is due in full upon exercise of all or any part of your vested Option. You may elect to make payment of such
aggregate Exercise Price in cash or by check or wire transfer (or any combination thereof). 
 4. WHOLE
SHARES. You may exercise your Option only for whole Shares. 
 5.
TERM. You may not exercise your Option before the commencement of its term on the Date of Grant or after its term expires. Subject to the provisions of the Plan and this Agreement, you may exercise all or any part
of the vested portion of your Option at any time prior to the earliest to occur of: 
 (a) the date on which your service with the
Company and its Affiliates is terminated for Cause or the date on which you breach any of the restrictive covenants set forth in Section 15 below; or 

(b) the Expiration Date indicated in the Grant Notice. 

 6. EXERCISE PROCEDURES AND
SUSPENSION. 
 (a) Subject to Section 7 below and other relevant terms and conditions of the
Plan and this Agreement, you may exercise the vested portion of your Option during its term by delivering a notice of exercise (in a form designated by the Company) together with the applicable Exercise Price therefor to the General Counsel, or to
such other person as the Company may designate, during regular business hours, together with such additional documents as the Company may then require. 

(b) By exercising your Option you agree that, as a condition to any exercise of your Option, you and your spouse, if requested by the
Company, contemporaneously with the exercise of your Option and prior to the issuance of any certificate representing the Shares purchased upon the exercise of your Option, shall execute any agreements by and among the Company and any of the
Company’s stockholders which shall then be applicable to the Shares to be issued to you, including any and all amendments to such agreements in effect at the time of such exercise, and agree to comply with any and all restrictions which then
apply to holders of Common Stock (or the Shares which at that time are to be issued upon the exercise of your Option). 
 (c) You
acknowledge that your ability to exercise the Option may be prohibited by the Company’s insider trading policy. 
 7.
CONDITIONS TO ISSUANCE OF STOCK. The Shares deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but
unissued shares or issued shares which have then been reacquired by the Company. Such Shares shall be fully paid and nonassessable. The Company shall not be required to issue or deliver any Shares purchased upon the exercise of the Option or make
book entries evidencing such Shares prior to fulfillment of all of the following conditions: 
 (a) The completion of any
registration or other qualification of such Shares under any state or federal law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Committee shall, in its absolute
discretion, deem necessary or advisable; 
 (b) The obtaining of any approval or other clearance from any state or federal
governmental agency which the Committee shall, in its absolute discretion, determine to be necessary or advisable; 
 (c) The
receipt by the Company of full payment for such Shares, including payment of any applicable withholding tax pursuant to Section 12 below; 

(d) The receipt by the Company of a lock-up agreement in substantially the form as attached to this Stock Option Agreement as
Exhibit A; and 
 (e) The lapse of such reasonable period of time following the exercise of the Option as the Committee may
from time to time establish for reasons of administrative convenience. 
 Notwithstanding anything to the contrary contained herein, you may not exercise
your Option if the terms of the Plan do not permit the exercise of Options, or if the Company exercises its rights under the Plan to suspend, delay or restrict the exercise of Options. 

  
 2 

 8. DOCUMENTS GOVERNING ISSUED
COMMON STOCK. The Shares that you acquire upon exercise of your Option are subject to the terms of the Plan, the Company’s bylaws, the Company’s certificate of incorporation, any agreement
relating to such Shares to which you become a party, or any other similar document. You should ensure that you understand your rights and obligations as a stockholder of the Company prior to the time that you exercise your Option. 

9. LIMITATIONS ON TRANSFER OF OPTIONS.
Subject to Section 15(b) of the Plan, your Option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to
the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to exercise your Option or any portion thereof. 

10. RIGHTS UPON EXERCISE. You will not have any rights to dividends or
other rights of a stockholder with respect to the Shares subject to your Option until you have given written notice of the exercise of your Option, paid in full for such Shares and, if applicable, satisfied any other conditions imposed by the
Committee pursuant to the Plan. 
 11. OPTION IS NOT A SERVICE
CONTRACT. Your Option is not a service contract, and nothing in your Option shall be deemed to create in any way whatsoever any obligation on your part to continue in the service of the Company or any of its
Affiliates, or of the Company or any of its Affiliates to continue your service. Nothing in your Option shall obligate the Company or any of its Affiliates, or their respective stockholders or Boards of Directors, to continue your relationship as a
director or consultant or otherwise for the Company or any of its Affiliates. 
 12. WITHHOLDING
OBLIGATIONS. 
 (a) At the time you exercise your Option, in whole or in part, or at any time
thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy any federal, state, local and foreign tax
withholding obligations of the Company or any of its Affiliates, which arise in connection with your Option. The Committee may, in its sole discretion and in satisfaction of the foregoing requirement, allow you to elect to have the Company withhold
Shares otherwise issuable under this Agreement (or allow the return of Shares) to satisfy tax withholding obligations. 
 (b) You
may not exercise your Option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied or appropriate arrangements (acceptable to the Company) are made therefor. 

13. NOTICES. Any notices provided under the terms of this Agreement or the Plan shall be given in writing
and shall be deemed effectively given upon receipt, or in the case of notices delivered by mail to you, five (5) days after deposit in the United States mail (or with another delivery service), certified or registered mail, return receipt
requested, postage prepaid, addressed to you at the last address you provided to the Company. 
 14. OPTION
SUBJECT TO PLAN. By entering into this Agreement, you agree and acknowledge that you have received and read a copy of the Plan. The Option is subject to the terms and provisions of the
Plan and such terms and provisions are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail. 

  
 3 

 15. RESTRICTIVE COVENANTS. In the event that
you breach a confidentiality, non-competition, non-solicitation, non-use or assignment of intellectual property, no-hire, or non-disparagement covenant in any agreement with the Company and/or any of its Affiliates (the “Restrictive
Covenants”), in addition to any other remedies specified in such agreements (including injunctive relief) or otherwise permitted by law, you will forfeit any outstanding Options and you will be required to pay to the
Company, within ten (10) business days following the latest of the date on which you engage in conduct prohibited under the Restrictive Covenants, the date of exercise of the Option, or the date of sale or other disposition of Shares received
upon exercise of the Option, an amount equal to the excess, if any, of (i) the aggregate proceeds you received (x) in connection with the exercise of the Option or (y) upon the sale or other disposition of the Shares received upon
exercise of the Option, in each case, including any dividends and distributions that you received in respect of such Shares, over (ii) the aggregate Exercise Price paid to acquire such Shares. You specifically recognize and affirm that strict
compliance with terms of the covenants set forth in the Restrictive Covenants is required in order for you to vest and receive the Shares. You agree that should all or any part or application of the Restrictive Covenants be held or found
invalid or unenforceable for any reason whatsoever by a court of competent jurisdiction in an action between you and the Company, you nevertheless shall not vest in and receive any of the Shares if you violated any of the terms of the covenants set
forth in the Restrictive Covenants. 
 16. CONSENT TO ELECTRONIC
DELIVERY. In lieu of receiving documents in paper format, you agree, to the fullest extent permitted by law, to accept electronic delivery of any documents that the Company may be required to deliver (including, but
not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other agreements, forms and communications) in connection with this and any other prior or
future incentive award or program made or offered by the Company or its predecessors or successors. Electronic delivery of a document to you may be via a Company e-mail system or by reference to a location on a Company intranet site to which you
have access. 
 17. SECTION 409A. For purposes of Section 409A of the Code, this Option is intended to be exempt from
Section 409A as a stock right under Treasury Regulation Section 1.409A-1(b)(5). The Committee may adopt such amendments to the Plan and this Agreement, and appropriate policies and procedures, including amendments and policies with
retroactive effect, that the Committee determines necessary or appropriate to preserve the intended treatment of this Option. 
 18.
MISCELLANEOUS. 
 (a) You agree upon request to execute any further documents or instruments
necessary or desirable in the sole determination of the Company to carry out the purposes or intent of this Agreement. 
 (b) You
acknowledge and agree that you have reviewed this Agreement in its entirety, have had an opportunity to obtain the advice of counsel and your personal tax advisor prior to executing and accepting your Option and fully understand all provisions of
your Option. You are solely responsible for paying all taxes in connection with the grant and exercise of your Option. 
 (c) The
waiver by either party of compliance with any provision of this Agreement by the other party shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by such party of a provision of this
Agreement. 
 (d) This Agreement shall inure to the benefit of and be binding upon the parties hereto and their legal
representatives, heirs, and permitted transferees, successors and assigns. 

  
 4 

 (e) This Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware, without giving effect to any conflict of laws provision or rule. 
 (f) This Agreement, including those documents
and agreements explicitly referenced herein, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements or understandings, whether written or oral. This Agreement may not be
amended, modified or revoked, in whole or in part, except by an agreement in writing signed by each of the parties hereto. 
 (g)
You acknowledge and agree that in the event of a Change in Control, the Committee may take certain actions with respect to the Option as permitted under the Plan and that the Committee’s actions with respect to your Award may differ from
those taken with respect to other Award Agreements or Participants. 
 (h) In administering the Plan, or to comply with applicable
legal, regulatory, tax or accounting requirements, it may be necessary for the Company or its Affiliates to transfer certain data to the Company or another Affiliate, or to its outside providers or governmental agencies. By accepting the Option, you
consent, to the fullest extent permitted by law, to the use and transfer, electronically or otherwise, of your personal data to such entities for such purposes. 

  
 5 

 Exhibit A — Form of Lock-up Agreement 

To Form of Stock Option Agreement 

[Insert Lock-up Agreement] 

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]